| |
Transform the Industry with Your Innovation! Submissions are now open for the Fierce Life Sciences Innovation Awards. Click to submit your entry and learn more about the categories and criteria.
|
|
Today’s Big NewsJul 29, 2024 |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Save up to $500 with Early Bird Rates. Register Now!
|
|
| By Angus Liu Pfizer is laying off 210 employees across two North Carolina manufacturing sites, including 150 people at the main facility involved in the recently failed DMD gene therapy program. |
|
|
|
By James Waldron Earlier this month, Flagship Pioneering hinted that another Big Pharma may soon join its growing fleet of collaborators. Now, GSK has sailed into view. |
By Conor Hale In the game of moneyed musical chairs, it’s clear the tempo has slowed. |
By Fraiser Kansteiner Amid an influx of new drugs targeting one of the believed root causes of Alzheimer’s disease, a new symptomatic med has hit the scene, courtesy of Vancouver’s Alpha Cognition. |
|
Sept. 25 - 26, 2024 | San Diego, CA Cutting-edge educational sessions: Gain insights from industry leaders. Early Bird Rate ends August 2nd, Save $400, Register Today!
|
|
By James Waldron Boehringer Ingelheim is paying up to $1.3 billion for Nerio Therapeutics and a preclinical immune checkpoint inhibitor program that the German pharma giant hopes will become the “centerpiece” of its immune-oncology portfolio. |
By Conor Hale While it won't replace a colonoscopy, the Shield test is designed to funnel adults ages 45 and up at an average risk for the disease toward the exam. |
By Nick Paul Taylor Eli Lilly is putting out a new message to mark the start of the Olympic Games: “You only get one body, let's fight like hell for it.” The Big Pharma, which is partnered with Team USA, put the message across in a 60-second ad about how any body can get sick—but nobody needs to accept that. |
By Darren Incorvaia Toxoplasma gondii is a protozoan parasite famous for its cunning ways. This microbial manipulator can only reproduce inside of cats, so, if it finds itself in another mammalian host, like a rat, it alters the rodent’s behavior to make it less fearful of felines. Now, researchers have devised a way to engineer this single-celled saboteur for good. |
By Angus Liu With a phase 3 win claimed by AstraZeneca, the heated BTK inhibitor race might see its first triplet regimen in chronic lymphocytic leukemia. |
By Annalee Armstrong With venture investments pouring into biopharma, steady M&A deals and an increasingly widening IPO market, J.P. Morgan sees the industry returning to growth—finally. |
By Nick Paul Taylor Kaléo’s engagement with Brittany Mahomes’ 2 million Instagram followers has landed it in the FDA’s bad books. After seeing a Mahomes’ Instagram post that “entirely [omitted] all risk information,” the agency sent (PDF) an untitled letter asking Kaléo to change the promotion of its EpiPen rival Auvi-Q. |
By Eric Sagonowsky After a prior skirmish over tax policy in England, AstraZeneca is now butting heads with officials in the country over innovative drug access. |
Fierce podcastsDon’t miss an episode |
| | In this week’s episode of “Podnosis,” Micky Tripathi, Ph.D., National Coordinator for Health Information Technology at HHS, chats with Executive Editor Heather Landi about ONC’s achievements over the past 20 years, the agency’s current top priorities, the rapid adoption of AI in healthcare and more. |
|
|---|
|
|
|
Wednesday, September 11, 2024 | 2pm ET / 11am PT As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. Join us for a deep dive into AI’s significant impact on streamlining clinical project management, revolutionizing the generation of crucial research outputs and accelerating drug discovery. Register now.
|
|
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperIn this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
| WhitepaperIn a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
